White House is to announce drug pricing deal with Regeneron (REGN)

The announcement of a drug pricing deal between the White House and Regeneron could signify a pivotal shift in pharmaceutical pricing policy, impacting investor sentiment toward the biotech sector.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Hapag-Lloyd (HLAG GY) CEO reiterates extra cost is around USD 50mln a week due to Middle East situation, and trying to pass some of that to customers

US centcom has redirected 33 vessels since start of blockade

White House is to announce drug pricing deal with Regeneron (REGN)

US sells 4-wk bills at high-rate 3.595%, B/C 2.98x; sells 8-wk bills at high-rate 3.605%, B/C 2.91x

European Closes: Euro Stoxx 50 -0.32% at 5,887, DAX -0.16% at 24,155, FTSE 100 -0.19% at 10,457, CAC 40 +0.87% at 8,227, AEX -0.70% at 1,014, IBEX 35 -0.67% at 17,886, FTSE MIB +0.26% at 47,907, SMI +1.38% at 13,248, PSI +0.25% at 9,209

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This may bolster Regeneron's outlook as it suggests governmental support, potentially influencing share performance and similar companies in the space. Market participants should assess how this aligns with broader trends in healthcare regulations and peer movements in equities.

Related headlines

The whole workspace, free to try.

Try it free